From the Desk of Evan Yu: Does PD-1/PD-L1 inhibition really work in prostate cancer?”
Early attempts at checkpoint inhibition in prostate cancer seemed to offer little promise. The initial trial with CTLA-4 inhibition with ipilumumab was performed in patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting and resulted in a HR 0.85, 95% CI 0.72-1.00; p=0.053.1
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medical Oncology, University of Washington School of Medicine
- Member, Fred Hutchinson Cancer Research Center
- Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.